Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 13, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements by the GlaxoSmithKline Employee Trust ("the GSK Trust") on behalf of employee plans:
- June 8, 2006: The GSK Trust transferred 112,300 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- June 9, 2006: The GSK Trust sold 2,382 Ordinary Shares on behalf of participants in the GlaxoSmithKline Share Value Plan at a price of GBP 14.93 per share.
- June 9, 2006: The GSK Trust transferred 10,280 Ordinary Shares to participants in the GlaxoSmithKline Share Value Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) are interested in shares held in the GSK Trust in the same capacity as other employees. The transactions were notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares transferred or sold by the GSK Trust during the reporting period (112,300 transferred; 2,382 sold; 10,280 transferred).
- Confirm the transaction price of GBP 14.93 per share for the June 9 sale.
- Note that the GSK Trust is a discretionary trust for current and former employees, and the filing does not indicate changes in direct beneficial ownership by the named directors themselves, but rather their interest in the trust.